Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) FCF Margin (2022 - 2026)

Indivior Pharmaceuticals has reported FCF Margin over the past 5 years, most recently at 9.15% for Q1 2026.

  • For Q1 2026, FCF Margin fell 3546.0% year-over-year to 9.15%; the TTM value through Mar 2026 reached 14.87%, down 2479.0%, while the annual FY2025 figure was 7.51%, 810.0% down from the prior year.
  • FCF Margin for Q1 2026 was 9.15% at Indivior Pharmaceuticals, up from 68.44% in the prior quarter.
  • Over five years, FCF Margin peaked at 46.69% in Q2 2025 and troughed at 105.8% in Q4 2023.
  • A 5-year average of 8.67% and a median of 3.73% in 2022 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: crashed -10207bps in 2023 and later soared 9473bps in 2024.
  • Year by year, FCF Margin stood at 3.73% in 2022, then tumbled by -2733bps to 105.8% in 2023, then soared by 90bps to 11.07% in 2024, then tumbled by -518bps to 68.44% in 2025, then surged by 87bps to 9.15% in 2026.
  • Business Quant data shows FCF Margin for INDV at 9.15% in Q1 2026, 68.44% in Q4 2025, and 18.79% in Q3 2025.